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Introduction
Since its discovery 27 years ago, NF-κB has been shown to regulate the expression of over 200 immune, growth and inflammation genes (1, 2) . The clinically silent onset of pancreatic cancer has been attributed to the upregulation of proinflammatory pathways such as NF-κB (3) . NF-κB is constitutively active in pancreatic cancer cell lines and pancreatic adenocarcinoma, but not in immortalized/nontumorigenic pancreatic epithelial cells or normal pancreatic tissues (4) . Pancreatic cancer cell lines show increased levels of NF-κB subunits compared to non-malignant proliferating intestinal cells (5) . These preclinical observations extend to pancreatic cancer patients: (i) High expression of RelA (NF-κB subunit p65) was observed in 64% of histologically or cytologically verified advanced unresectable and/or metastatic disease and (ii) this correlates with increased expression of NF-κB target genes and poor prognosis in this patient subgroup (6, 7) . Conversely, down regulation of NF-κB (RelA) using siRNA sensitizes a subset of pancreatic cancer cells and pancreatic tumors in nude mice to gemcitabine (8, 9) . Inhibiting constitutive NF-κB activity suppressed growth, angiogenesis and metastasis of pancreatic cancer (10) .
IκB kinase β (IKKβ) is a key kinase in the NF-κB pathway that is activated by proinflammatory cytokines such as tumor necrosis factor α (TNFα) (11) . Upon activation IKKβ phosphorylates IκBα which leads to βTrCP mediated ubiquitination and proteasomal degradation of IκBα (12, 13) . Degradation of IκBα releases NF-κB, which translocates to the nucleus to activate gene expression (14) . TNFα mediated activation of IKKβ is also known to result in phosphorylated tuberous sclerosis 1 (TSC1). The phosphorylation mediated suppression of TSC1 results in the activation of the mTOR pathway (15) (16) (17) . Collectively these data suggest that IKKβ is a key node and upon activation by TNFα regulates transcription of genes through the p-IκBα / NF-κB axis and translation of the gene products through the mTOR / p-S6K / p-eIF4EBP axis.
The KRAS gene is mutated in > 90 % of pancreatic carcinomas. Targeted inactivation of IKKβ in Kras G12D mice stalled PanIN lesions from developing into pancreatic ductal adenocarcinoma (PDAC) (18, 19) . This establishes the mechanistic link between IKKβ and Kras mutations in the initiation of PDAC. This along with the observation that TNFα is found in ~50% of surgically resected tumor samples (16) makes a strong case for IKKβ as a target for pancreatic cancer therapeutic development.
Since its discovery the pharmaceutical industry has aggressively pursued the development of IKKβ inhibitors to treat diseases driven by chronic inflammation (20) .
Although several inhibitors passed the gamut of preclinical studies required to move compounds to the clinics only three of them were evaluated in the clinics and so far none have received FDA approval (21) . One possible reason for this is the observed toxicity (ML-120B and TPCA1) in preclinical models (22, 23) . Chronic administration of IKKβ results in granulocytosis and endotoxin-mediated mortality (23, 24) . In the present study we characterize the mechanism of action and antitumor activity of an IKKβ inhibitor, , which has a quinoxaline urea chemotype. More importantly prolonged administration of showed no detectable toxicity.
Research. 
Materials and Methods

Chemicals and Reagents:
The quinoxaline urea analog 13-197 was synthesized and purified (> 98%) as previously described (25, 26) . Efavirenz (EFV) was obtained from Hetero Labs Ltd. (Hyderabad, India). HPLC-grade methanol, acetonitrile, ammonium acetate, ammonium formate, ammonium hydroxide, formic acid, and acetic acid were obtained from Fisher Scientific (Fair Lawn, NJ, USA).
Cell lines and culture conditions: Human pancreatic cancer cell lines Capan-2, MiaPaCa2, AsPC1, Hs766T and SUIT2 were cultured in Dulbecco's modified eagles medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and 100 µg/mL streptomycin.
RBC Kinase assay:
The appropriate substrate was freshly prepared in the kinase assay buffer (20 mM HEPES pH 7.5, 10 mM MgCl 2 , 1 mM EGTA, 0.2 % Brij35, 0.02 mg/mL BSA, 0.1 mM Na 3 VO 4 , 2 mM DTT, 1% DMSO and the required cofactors added individually for each kinase reaction). The kinase was added to the solution and gently mixed and the compounds were then added in DMSO (final DMSO concentration of 1.4 %). 33 P-ATP (specific activity 0.01 µCi / µl final) was added to the mixture and incubated for 2 h at room temperature. Kinase reaction was then spotted onto P81 ion exchange paper (Whatman # 3698-915) washed extensively in 0.75 % phosphoric acid and read on a scintillation counter.
For the follow up screen, 10 mM DMSO solution of the compound was titrated 1:3 over 10 points into wells containing 100% DMSO. The diluted compounds were delivered into the reaction at 100 µM starting concentration with 1:3 serial dilution with the final DMSO concentration of 2.2%. Western blot analysis: Cells were harvested on ice in Buffer A (10 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 2 mM DTT) containing protease and phosphatase inhibitors.
The cells were allowed to swell on ice for 30 min, 1% NP-40 was added, and the samples were centrifuged in the cold. The resulting supernatant was transferred to a new tube and designated as the cytoplasmic fraction. To the remaining pellet, Buffer C (20 mM HEPES, 420 mM NaCl, 5 mM EDTA, 5 mM DTT, 10% glycerol) containing protease and phosphatase inhibitors was added. The samples incubated on ice with intermittent agitation over a period of 30 min and were then centrifuged in the cold. The resulting supernatant was designated the nuclear fraction. All samples were stored at -20°C until needed. Western blot analyses were carried out as described previously with minor modifications (26, 27) . Briefly, cytoplasmic and nuclear lysates were prepared from control and 13-197 treated cells by using nuclear extract kit (active motif). The cell lysates (50 μg) were resolved in 4% -20% denaturing polyacrylamide gel (Bio-Rad) and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore). The blotted membranes were incubated with the following antibodies, mouse monoclonal anti-NF- In vitro migration assay: Migration assay was performed by using polyethylene terapthalate (PET) transwell inserts as described previously (27) . In vitro invasion assay: Pancreatic cancer cells invasion assay was evaluated by matrigel coated boydon chamber assay as described previously (27) . used for sample analysis. A hybrid ion trap-triple quadrupole (Q-Trap) MS was used to quantify all analytes by multiple reaction monitoring (MRM). For sample preparation, 1 ml of ice-cold ACN was added to 100 μl plasma samples pre-spiked with 4.0 µg/ml IS (EFV). Samples were then vortexed, and centrifuged at 16,000 × g for 10 min. The supernatant was aspirated, evaporated under vacuum, and reconstituted in a 100 μl 75% methanol. After centrifugation at 16,000 × g for 10 min, 10 μl of each sample was used for LC-MS/MS analysis. Liver, kidney, lung, heart, spleen and brain tissues were 
Results and Discussion
13-197 inhibits IKKβ and targets NF-κB and mTOR pathway proteins.
Screening a focused library of quinoxaline analogs against a panel of cancer cell lines led to the identification of Figure 1A . The IC 50 values were in the low-μM range for four (TRKA, IKKβ, EPHA6 and Nek3) of the six kinases identified as hits. EPHA6 is highly expressed in the brain and is important for learning and memory (31) . Nek3 is important in prolactin-mediated motility of cells and inhibiting Nek3 might be beneficial for a cancer therapeutic (32) . We focused on the kinases TRKA and IKKβ as they had the lowest IC 50 values at 1.9 ± 0.2 μM and 3.0 ± 0.1 μM respectively. Although TRKA is primarily localized to the brain, both TRKA and IKKβ are activated by cytokines (IL-1 and TNFα), which promote NF-κB mediated gene expression (33, 34) .
TNFα stimulation regulates transcription via the p-IKKβ / p-IκBα / NF-κB axis and translation via the p-IKKβ / mTOR / p-S6K / p-eIF4EBP axis ( Figure 1B) (16, 35) . TNFα is commonly found in the tumor microenvironment of pancreatic tumors and leads to activation of the canonical NF-κB pathway (18, 19) . Therefore if IKKβ is inhibited by in pancreatic cancer we expected to observe inhibition of IκBα, S6K and eIF4EBP1 and PARP/H2B ( Figure 1C ). As expected we observed decreased nuclear levels of p65.
To determine if this leads to inhibition of NF-κB mediated gene expression we evaluated 13-197 in a NF-κB luciferase assay (28) . A cancer cell line that is specifically designed to monitor the activity of NF-κB in response to TNF-α was treated with 13-197 for 2h followed by TNFα for an additional 4h. Under multiplexing conditions the cells were assayed for viability using Alamar Blue and the NF-κB transcription activity using the ONE-Glo luciferase system ( Figure 1D ). The results show that 13-197 inhibits TNFα stimulated NF-κB mediated luciferase expression with an IC 50 value of 8.4 ± 1.2 μM.
Together these results show that 13-197 targets IKKβ which is upstream of NF-κB nuclear translocation and thereby inhibits NF-κB mediated transcription. To determine inhibition of the mTOR pathway we probed MiaPaCa2 lysates for phosphorylated S6K and eIF4EBP1 treated with 13-197 for 4 and 24h ( Figure 1C) . The results showed decreased phosphorylation of S6K and eIF4EBP1. In summary the data suggests that 
13-197 inhibits MiaPaCa2 cell growth by arresting cells in the G1 phase
We next explored if IKKβ inhibition by results in the inhibition of pancreatic cancer cell growth. A panel of pancreatic cancer cell lines subjected to showed inhibition of cell growth with μM potencies (Table S1) Consistent with the G1 arrest we observed reduced levels of the corresponding cell cycle markers E2F, PCNA and Cyclin D1 ( Figure 2B ) (36) . Together the data demonstrate that 13-197 inhibits pancreatic cancer cell growth by inducing G1 arrest of cells.
13-197 down regulates expression of antiapoptotic proteins and induced apoptosis in MiaPaCa2 cells
Next we probed the effect of 13-197 on apoptotic pathway proteins. Mcl-1 and Bcl-xL are antiapoptotic proteins that sequester the proapoptotic proteins (Bax / Bak) (37) . XIAP and Survivin belong to the IAP family and are inhibitors of caspase activation (38) . In MiaPaCa2 cells treated with 13-197, we observed a significant decrease in the and MMP-9 that are implicated in angiogenesis, invasion and metastasis (39, 40) . We observed that 13-197 inhibited both the invasion and migration of MiaPaCa2 cells by about 50% (Figure 2D ). This suggests that has the potential to not only inhibit growth of tumors but also inhibit metastasis.
13-197 is orally available with extensive distribution to peripheral tissues
Pharmacokinetic (PK) difficulties account for more than 50% of drug development failures preventing new chemical entities (NCEs) from reaching the market, whereas toxicity issues and lack of efficacy account for only 30% of development failures (41) . As a result, in addition to paying attention to the traditional concern of attaining potency and selectivity towards the biological target of interest, PK considerations have been moved to early stages of drug discovery, a significant paradigm shift in the pharmaceutical industry (42) .
Lipinski's rule of five serves as a guide to determine if compounds will be orally bioavailable (43). Lipinski's rule states a compound with the following properties, molecular weight (M. Wt.) <500 Da, < 5 hydrogen bond donors, < 10 hydrogen bond acceptors and a log P (an octanol-water partition coefficient) < 5 is likely to be orally available. Analysis of 13-197 (M. Wt. = 474 Da, hydrogen bond donors = 2, hydrogen bond acceptors = 7 and log P = 3.94), suggested that it would be orally available. was formulated in cremaphor EL, which is a commonly used excipient in drugs for PK and tissue distribution studies.
A mass spectrometry method was established to determine 13-197 levels in plasma and tissue. Mice were dosed orally with 150 mg / Kg of 13-197 and sacrificed at indicated time points. 13-197 levels in blood and various tissue samples were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) ( Figure   3A and 3B). The PK properties of 13-197 are described as an inset in Figure 3A and the tissue levels as an inset in Figure 3B . Although low (~ 5%) the results show that is orally available, and demonstrates extensive distribution to peripheral tissues, especially liver and kidney, which are the primary organs of elimination.
Maximum tolerated dose of 13-197 under acute administration
Since IKKβ inhibitors ML-120B and TPCA1 showed toxicity in mice (22, 23) we conducted a preliminary dose-escalation study to assess acute toxicity in Balb/c mice.
Mice were gavaged with increasing 13-197 doses (vehicle, 150, 450 and 900 mg/Kg) and monitored for 24 h at which time they were sacrificed and plasma isolated. All the mice were alive and none of the mice, even at the highest dose, showed any visible signs of toxicity. Since the PK studies showed clearance through the liver the levels of 
Alanine transaminase (ALT) and aspartate transaminase (AST), the plasma biochemical markers for hepatotoxicity were measured (44) . Leakage of ALT and / or AST into the blood stream indicates liver damage. Plasma ALT and AST were measured in vehicle and 13-197 treated Balb/c mice are within error range indicating a lack of hepatotoxicity (data not shown). Together these show that the MTD for 13-197 is > 900 mg/Kg.
13-197 does not induce granulocytosis and protects mice from LPS-induced mortality
Prolonged treatment (twice daily for 4 days) with the Millennium IKKβ inhibitor ML-120B resulted in granulocytosis and LPS-induced mortality (23, 24) . This is because chronic inhibition of IKKβ in neutrophils results in the processing of pro-IL-1β to IL-1β by the serine protease PR3. This was shown to induce a feed forward loop upon LPS treatment resulting in a sustained release of IL-1β from macrophages leading to death (23) . We treated 13-197 twice daily for 4 days and measured neutrophil levels by blood smears. The mice were then challenged with LPS. Our results did not show an increase in the neutrophil levels in the treated mice when compared to control mice (Table S2 ).
More importantly we observed a protective effect from LPS-induced mortality in mice pre-treated with (Figure 4A ).
To gain insight into this protective effect, we investigated the effect of IκBα phosphorylation in cells treated with and without 13-197 followed by TNFα stimulation.
In the control experiment HEK293 cells were treated with DMSO followed by TNFα we observes a significant reduction in phospho-IκB levels (last two lanes of the gel) when compared to DMSO treated lanes (box, Figure 4B ). This suggests that does not inhibit the transient activation of IKKβ but inhibits IKKβ post activation which is probably found under sustained stimulation. The inhibition by 13-197 is unlike other known IKKβ inhibitors such as TPCA1 ( Figure 4C ) that completely blocks TNF-α induced phosphorylation of IkBα (46, 47) . This suggests that does not block the transient activation of the pathway in neutrophils and thereby protects them from LPS induced mortality.
13-197 reduced tumor growth and metastasis in an orthotopic pancreas cancer model
Once we established that 13-197 is non-toxic and orally available, we evaluated its ability to reduce tumor growth and metastases in orthotopic pancreas cancer model. MiaPaCa2 cells were placed in the pancreas of nude mice and the mice were allowed to heal after surgery. The tumors were allowed to grow for 2 weeks at which time they were palpable. The tumor bearing mice were randomized and half the animals were treated orally with volumes were measured. We observed ~50% reduction in both the tumor weight and volume in the 13-197 treated animals compared to vehicle treated animals ( Figure 5A ).
We also found fewer tumor nodules in other organs of 13-197 treated animals compared to vehicle treated animals (Table S3 ). The in vivo effects are consistent with the in vitro data, which suggested inhibition of tumor growth and metastases by 13-197. Proliferation index and microvessel density are measures of the number of cells dividing in the tumor and angiogenesis respectively. We observed a reduction of both Ki67 and CD31 in 13-197 treated tumors compared to vehicle controls ( Figure 5B and 5C ).
Immunohistochemistry studies showed that 13-197 treated tumors had reduced levels of Mcl-1 (NF-κB target gene) and phospho-S6 ribosomal protein (mTOR target) as compared to vehicle treated tumors ( Figure 6A and Table S4 ). This suggests that 13-197 perturbs both the NF-κB and mTOR signaling in vivo and is consistent with cellbased studies. The pathologist was blinded and the tumor tissues were scored for inflammation and necrosis. The results indicate 13-197 suppresses inflammation and increases necrosis in 13-197 treated mice (Table S5) . These results are consistent with the inhibition of NF-κB. We also determined the 13-197 levels in the pancreas, liver and serum at the end of the study ( Figure 6B ). Consistent with our PK data the highest drug levels were found in the Liver. Therefore, to probe for hepatotoxicity, we measured the levels of ALT and AST in 13-197 and vehicle treated mice. We did not observe a difference in the ALT or AST levels in 13-197 treated mice when compared to vehicle treated mice, indicating the absence of hepatotoxicity ( Figure 6C ). We also conducted a macroscopic examination of the organs and found no obvious toxicity in the treated animals. 
